Previous 10 | Next 10 |
Micro-cap eyecare pharmaceutical company Harrow Health ( NASDAQ: HROW ) and Swiss injectable medicines firm Sintetica on Tuesday said the U.S. FDA had approved their gel for anesthesia of the surface of the eye. Shares of HROW jumped 27.3% to $9.69 in afternoon trading...
IHEEZO™ Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly 14 Years IHEEZO™ was Licensed by Harrow for the U.S. and Canadian Mar...
Michigan Value Investor is a value oriented fund manager who has recently launched a new marketplace service: Concentrated Value with MVI. Why the distinction between growth and value is artificial, how to identify opportunities that the market isn’t even aware of and his excel...
In 2021 Harrow Health began to expand into branded pharmaceutical products (BPP) by acquiring the rights to several new products. The expansion into BPP has led to increased costs. With HROW stock down roughly 45% from its highs, I believe the market is missing the forest for the ...
SRK Capital, LLC provides investment management services to an investment partnership, SRK Fund I, LP. SRK Fund I, LP declined -17.57% during the first half of 2022. Permanent capital loss is not equal to stock price quotational loss (which I pay little attention to). The pres...
Harrow Health, Inc. (HROW) Q2 2022 Earnings Conference Call August 9, 2022 4:45 P.M. ET Company Participants Jamie Webb - Director of Communications and Investor Relations Mark Baum - Chief Executive Officer and Chairman of the Board Andrew Boll - Chief Financial...
Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medicines, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, wil...
Harrow Health press release ( NASDAQ: HROW ): Q2 Non-GAAP EPS of $0.01 (vs. $0.07 Y/Y). Revenue of $23.3M (+28.7% Y/Y). For further details see: Harrow Health Q2 Non-GAAP EPS down Y/Y, revenue up
Revenues Increase for Eighth Consecutive Quarter Highlights for Second Quarter 2022: Record revenues of $23.3 million, up 29% over $18.1 million for the prior‑year quarter Record gross profit of $16.8 million, up 22% over $13.7 million for the prior‑year ...
Harrow Health, Inc. (Nasdaq: HROW), an eye health pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medications that are accessible and affordable, today announced that it will release its financial results for th...
News, Short Squeeze, Breakout and More Instantly...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...